Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JM-010 for Dyskinesia in Parkinson's Disease (ASTORIA)
NCT03956979Phase 2Completed
- Sponsor
- Contera Pharma
- Start
- Jul 2019
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of buspirone and zolmitriptan in levodopa-induced dyskinesia (LID) (3 arms), sponsored by Contera Pharma. Primary endpoint: Unified Dyskinesia Rating Scale at 12 weeks. Started Jul 2019; status: completed.
02
Drugs
buspironezolmitriptan
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT03956979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03956979.